Foundayo being studied for OSA

Obstructive sleep apnea is what happens when the throat keeps collapsing during sleep, like a soft straw pinching shut over and over, and doctors track the problem with the apnea-hypopnea index, which counts how many times breathing partly or fully stops each hour. The strongest risk factor for obstructive sleep apnea is obesity, because fat around the neck and tongue can narrow the airway before sleep even starts. The standard treatment is positive airway pressure, a bedside machine that pushes air through a mask to keep the throat open. Eli Lilly is now testing its oral drug orforglipron, sold in the United States as Foundayo, in people with moderate-to-severe obstructive sleep apnea who also have obesity or are overweight. The sleep apnea program is called ATTAIN-OSA and is listed as a phase 3 trial. Orforglipron belongs to the glucagon-like peptide-1 class, which is a gut-hormone mimic that tells the brain and stomach “meal is over” sooner than usual. Lilly’s approved use for Foundayo is weight management, but the sleep apnea trial is asking whether weight loss from a pill can also cut nighttime breathing interruptions. (ManagedHealthcareExecutive.com/view/the-fda-has-approved-eli-lilly-s-oral-glp-1-let-the-heated-rivalry-with-oral-wegovy-begin) The ATTAIN-OSA program is split into two studies because sleep apnea patients do not all live the same way. One study enrolls people who cannot or will not use positive airway pressure, and the other enrolls people who have already been using positive airway pressure for at least 3 months and plan to stay on it. The main yardstick is concrete: researchers are measuring the change in apnea-hypopnea index after treatment, not just whether patients say they feel better. Eligible participants need an apnea-hypopnea index of at least 15 events per hour and a body mass index of at least 27 kilograms per square meter. Lilly already has a clue this strategy can work because its injectable drug tirzepatide, sold as Zepbound, won United States approval in December 2024 as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. That approval was based on trials showing fewer breathing interruptions along with weight loss. What changes with Foundayo is the form factor. Zepbound is a weekly injection, while orforglipron is a once-daily pill, so Lilly is testing whether sleep medicine can move from masks and shots toward tablets for some patients. (BioSpace.com/press-releases/foundayo-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-u-s) The trial record says ATTAIN-OSA is active but not recruiting, which usually means enrollment is complete and the study is being run through follow-up and data collection. No results are posted yet, so the story right now is not that the pill works for sleep apnea, but that Lilly has advanced the question into late-stage testing. If the numbers come through, the next expansion for glucagon-like peptide-1 drugs will not be another scale reading but a sleep-lab metric. That would turn a weight-loss pill into a sleep apnea drug for a condition that has long been treated mainly with masks, mouth devices, and surgery.